China Diagnostic Reagent Industry Report, 2012-2014
  • Jan.2013
  • Hard Copy
  • USD $2,200
  • Pages:86
  • Single User License
    (PDF Unprintable)       
  • USD $2,100
  • Code: XJT025
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,400

China’s diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China’s medical care investment and per capita health care spending, the China’s diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China’s diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

Market Scale of In Vitro Diagnostic Reagent in China, 2007-2015

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China’s diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis. Meanwhile, China’s in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively.

As a high-tech industry, the profitability of the overall Chinese diagnostic reagent industry is high. In 2011, among major Chinese diagnostic reagent enterprises, KHB, Da An Gene, BioSino, Kinghawk, Livzon, Leadman all achieved a gross margin of more than 50%; Fosun Pharma reached a gross margin of 40.4%, since diagnostic reagent and instrument business accounts for a lower proportion of its revenue. With the improvement of industry concentration, it’s expected that the advantageous enterprises with strong capability of technological innovation and large production scale will obtain higher market share and profitability.

China Diagnostic Reagent Industry Report, 2012-2014 mainly includes the following contents:

--Market scale, market structure, import and export, competitive landscape, profitability, entry barriers of China’s diagnostic reagent industry;
--Regulatory system and policy, industry policy, industrial chain, upstream and downstream of China’s diagnostic reagent industry;
--Development forecast of China’s diagnostic reagent industry, including the forecast of market scale, major market segments, industry competition, and enterprise development trends;
--Production, operation, investment, M&A, diagnostic reagent business and development prospect of 15 Chinese diagnostic reagent enterprises.

1. Overview of Diagnostic Reagent Industry
1.1 Definition 
1.2 Classification 

2. China Diagnostic Reagent Industry
2.1 Overview 
2.2 Market Structure 
2.3 Import and Export 
2.3.1 Import 
2.3.2 Export 
2.4 Competitive Landscape 
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability 
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers 

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment 
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries 
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast 
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry 
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win 

5. Major Chinese Diagnostic Reagent Enterprises 
5.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB) 
5.1.1 Profile
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 Gross Margin 
5.1.5 R & D and Investment 
5.1.6 Customers 
5.1.7 Diagnostic Reagent Business 
5.1.8 Forecast and Prospect
5.2 Da An Gene Co., Ltd.
5.2.1 Profile
5.2.2 Operation 
5.2.3 Revenue Structure 
5.2.4 Gross Margin 
5.2.5 R & D and Investment 
5.2.6 Diagnostic Reagent Business 
5.2.7 Forecast and Prospect
5.3 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.3.1 Profile
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 Gross Margin 
5.3.5 R & D and Investment 
5.3.6 Diagnostic Reagent Business 
5.3.7 Forecast and Prospect
5.4 BioSino Bio-technology and Science Inc.
5.4.1 Profile
5.4.2 Operation 
5.4.3 Revenue Structure 
5.4.4 R & D and Investment 
5.4.5 Forecast and Prospect
5.5 Beijing Kinghawk Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Operation 
5.5.3 Revenue Structure 
5.5.4 Gross Margin 
5.5.5 Diagnostic Reagent Business 
5.5.6 Forecast and Prospect
5.6 Livzon Pharmaceutical Group Inc.
5.6.1 Profile
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 Gross Margin 
5.6.5 Diagnostic Reagent Business 
5.6.6 Forecast and Prospect
5.7 Beijing Leadman Biochemistry Co., Ltd.
5.7.1 Profile
5.7.2 Operation 
5.7.3 Revenue Structure 
5.7.4 Gross Margin 
5.7.5 R & D and Investment 
5.7.6 Customers 
5.7.7 Diagnostic Reagent Business 
5.7.8 Forecast and Prospect
5.8 Acon Biotech (Hangzhou) Co., Ltd.
5.8.1 Profile
5.8.2 Operation 
5.8.3 Development 
5.9 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
5.9.1 Profile
5.9.2 Operation 
5.9.3 Development 
5.10 Shanghai Rongsheng Biotech Co., Ltd. (Rsbio)
5.10.1 Profile
5.10.2 Operation 
5.10.3 Development 
5.11 Shenzhen PG Biotech Co., Ltd.
5.11.1 Profile
5.11.2 Operation 
5.12 Shanghai Upper Bio-Tech Pharma Co., Ltd.
5.12.1 Profile
5.12.2 Operation 
5.12.3 Development 
5.13 Inverness Medical (Shanghai) Co., Ltd.
5.13.1 Profile
5.13.2 Operation 
5.14 Blue Cross Bio-Medical (Beijing) Co., Ltd.
5.14.1 Profile
5.14.2 Operation 
5.14.3 Development 
5.15 Beijing North Institute of Biological Technology (BNIBT)
5.15.1 Profile
5.15.2 Operation 
5.15.3 Development 

Classification of In Vitro Diagnostic Reagents by Test Principle/Method
In Vitro Diagnostic Reagent Categories and Products by National Policy
Revenue of China’s Biological Product Industry, 2005-2012 
Market Scale of China’s In Vitro Diagnostic Reagent Industry, 2007-2011 
Market Structure of China’s In Vitro Diagnostic Reagent Industry, 2011 
China’s Import Volume of Diagnostic Reagent, 2007-2012 
China’s Import Value of Diagnostic Reagent, 2007-2012 
China’s Import Price of Diagnostic Reagent, 2007-2012 
China’s Import Volume, Import Value and Unit Import Price of Diagnostic Reagent by Country/Region, 2011 
China’s Export Volume of Diagnostic Reagent, 2007-2012 
China’s Export Value of Diagnostic Reagent, 2007-2012 
China’s Average Export Price of Diagnostic Reagent, 2007-2012 
China’s Export Volume, Export Value and Unit Export Price of Diagnostic Reagent, 2011
Competitive Landscape of China’s Diagnostic Reagent Industry
Diagnostic Reagent Business Revenue of Major Enterprises in China, 2011
Market Share of Major Enterprises in China’s Diagnostic Reagent Industry, 2011
Consolidated Gross Margin of Major Enterprises in China’s Diagnostic Reagent Industry, 2008-2012 
Major Regulatory Policies in China’s Diagnostic Reagent Industry, 2001-2012 
Main Policies in China’s Diagnostic Reagent Industry, 2005-2012 
Diagnostic Reagent Industry Chain 
China’s Hospital Quantity, 1980-2011
China’s Hospital Quantity by Grade, 2011
China’s Medical and Health Expenses, 1980-2011
China’s Medical and Health Expenses as a Percentage of GDP, 1985-2010
Total Personal Health Expenditure of Residents in China, 1980-2010
Per Capita Health Care Spending of China’s Urban and Rural Residents, 1990-2010
Per Capita Health Care Spending of China’s Urban and Rural Residents as a Percentage of Consumer Expenditure, 1990-2010
China’s Hospital Diagnosis and Treatment Quantity, 2005-2011
China’s Hospital Admissions, 2005-2011
China’s Population Aged above 65 and % of Total Population, 1982-2010
China’s Bi-weekly Incidence of Disease by Age 
Market Scale of China’s In Vitro Diagnostic Reagent Industry, 2007-2015
Diagnostic Reagent Product Structure of Mature Market, 2011
Market Scale of Major In Vitro Diagnostic Reagent Varieties in China, 2008-2012
Products and Revenue of Global Major Diagnostic Reagent Manufacturers
Development Course of Roche Diagnostics
Integrated Development Strategy of Global Leading Diagnostic Reagent Company
Revenue and Net Income of KHB, 2008-2012 
Revenue of KHB by Product, 2008-2012 
Revenue of KHB by Region, 2010-2012 
Gross Margin of KHB by Product, 2008-2012 
R&D Expenditure and % of Revenue of KHB, 2008-2012 
Sales of KHB from Top 5 Customers, 2008-2012
Name List, Revenue Contribution and % of KHB’s Top 5 Customers, 2011
Main Products and Time to Market of KHB, 1989-2012
Main Businesses and Products of KHB, 2011
Medical Equipment Types and Products of KHB, 2012
Growth Rates of KHB’s Diagnostic Reagent Revenue and National Diagnosis and Treatment Quantity, 2005-2011
Revenue and Net Income of KHB, 2011-2014 
Revenue and Net Income of Da An Gene, 2008-2012 
Revenue of Da An Gene by Product, 2008-2012 
Revenue of Da An Gene by Region, 2008-2012 
Gross Margin of Da An Gene by Product, 2008-2012 
R&D Expenditure and % of Revenue of Da An Gene, 2008-2012 
New Product Approval Document Type and Quantity of Da An Gene, 2007-2012
Main Assets and Businesses of Da An Gene 
Industrial Chain of Da An Gene 
Revenue and Net Income of Da An Gene, 2011-2014
Revenue and Net Income of Fosun Pharma, 2008-2012 
Revenue of Fosun Pharma by Product, 2008-2012 
Revenue of Fosun Pharma by Region, 2008-2012 
Gross Margin of Fosun Pharma by Product, 2008-2011 
R&D Expenditure and % of Revenue of Fosun Pharma, 2008-2012 
Revenue and Net Income of Fosun Pharma, 2011-2014 
Revenue and Profit of BioSino, 2008-2012
Revenue of BioSino by Product, 2008-2012 
R&D Expenditure and % of Revenue of BioSino, 2008-2012 
Revenue and Profit of BioSino, 2011-2014
Revenue and Net Income of Kinghawk, 2008-2012 
Revenue of Kinghawk by Product, 2010-2012 
Gross Margin of Kinghawk by Product, 2010-2011 
Revenue and Net Income of Kinghawk, 2011-2014 
Revenue and Net Income of Livzon, 2008-2012
Revenue of Livzon by Product, 2008-2012 
Revenue of Livzon by Region, 2008-2012
Gross Margin of Livzon by Product, 2008-2011
Main Diagnostic Reagent Products of Livzon
Revenue and Net Income of Livzon, 2011-2014
Revenue and Net Income of Leadman, 2008-2012
Revenue of Leadman by Product, 2008-2012
Gross Margin of Leadman by Product, 2008-2011
R&D Expenditure and % of Revenue of Leadman, 2008-2012
Sales of Leadman from Top 5 Customers, 2008-2012
Name List, Revenue Contribution and % of Leadman’s Top 5 Customers, 2011
Dealers of Leadman, 2008-2011
Revenue and Net Income of Leadman, 2011-2014
Revenue and Total Profit of Acon, 2007-2009
Gross Margin of Acon, 2007-2009
Total Assets and Liabilities of Acon, 2007-2009
Revenue and Total Profit of Wantai, 2007-2009
Gross Margin of Wantai, 2007-2009
Total Assets and Liabilities of Wantai, 2007-2009
Revenue and Total Profit of Rsbio, 2007-2009
Gross Margin of Rsbio, 2007-2009
Total Assets and Liabilities of Rsbio, 2007-2009
Revenue and Total Profit of PG Biotech, 2007-2008
Gross Margin of PG Biotech, 2007-2008
Total Assets and Liabilities of PG Biotech, 2007-2008
Revenue and Total Profit of Upper Bio-Tech, 2008-2009
Gross Margin of Upper Bio-Tech, 2008-2009
Total Assets and Liabilities of Upper Bio-Tech, 2008-2009
Revenue and Total Profit of Inverness Medical (Shanghai), 2007-2009
Gross Margin of Inverness Medical (Shanghai), 2007-2009
Total Assets and Liabilities of Inverness Medical (Shanghai), 2007-2009
Revenue and Total Profit of Blue Cross, 2007-2009
Gross Margin of Blue Cross, 2007-2009
Total Assets and Liabilities of Blue Cross, 2007-2009
Revenue and Total Profit of BNIBT, 2007-2009
Gross Margin of BNIBT, 2007-2009
Total Assets and Liabilities of BNIBT, 2007-2009

China Diagnostic Reagent Industry Report, 2011-2012

Diagnostic reagent can be divided into in vitro diagnostic (IVD) reagent and in vivo diagnostic reagent, wherein the former always holds a larger market share in China, accounting for 92.6% in the ove...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

China CT Industry Report, 2012-2014

Along with the in-depth implementation of new medical reform, the potential demand in central and western China and rural areas has been further released, and the medical diagnosis, monitoring and tre...

China Dental Industry Report, 2014-2018

Oral industry refers to the medical industry chain on the basis of oral medical consumption, mainly covering oral medical apparatus (equipment and consumables) and oral medical services. As reform of ...

China Medical Monitor Industry Report, 2014-2017

With advancement of medical reform, improvement of spending power, and enhancement of health care consciousness, China’s medical monitor industry is gradually expanding. During 2007-2013, the market s...

China Independent Clinical Laboratory Industry Report, 2014-2017

The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there...

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号